Search results Search for: Search Refine your results by duration: Any Under 5 mins Under 20 mins Over 20 mins Sort by: Relevance Views Date Operational Excellence in Process Development in Drug Substance Production Presented by Ken Green, Ph.D, Head of MSAT at Samsung Biologics and Klaus Mauch, CEO at Insilico Biotechnology AG This presentation will highlight Samsung Biologics (SBL) approach to align process development activities with technology transfer and cGMP manufactur... 6 months ago | 107 mins Property Searching in Reaxys and Related Chemistry Databases Prof. Damon. D. Ridley How do we find reliable spectroscopic, physico-chemical or biochemical properties of chemical substances quickly? Prof. Damon Ridley will walk us thro... 8 months ago | 60 mins Novel Technologies That Aid the Detection and Differentiation of Proteinaceous.. Danny Chou, President and Founder at Compassion BioSolution, LLC Full Title: Novel Technologies That Aid the Detection and Differentiation of Proteinaceous Impurities in Biologic Drug Substances and Drug Product Pr... 8 months ago | 87 mins Evaluating Reliability of Buried Steel Structures Based on Diffusion Theory Naresh Samtani, Ph.D., P.E., D.GE, F.ASCE, Owner & President of NCS GeoResources All design specifications for steel-reinforced concrete structures provide guidelines for the thickness of minimum concrete cover over the reinforcing... 5 months ago | 73 mins Mycoplasma Testing: Past, Current, and Future State Kenneth Tai at Kite Pharma, Lori Daane at BioMerieux and Alexander Bartes at Roche Pharma For nearly 30 years, mycoplasma testing for biologics have been performed using cell culture-based methods. The compendial mycoplasma detection metho... 3 months ago | 122 mins Cut through the hype surrounding AI and Identity Security OneLogin's Product Manager, Rich Chetwynd, and Forrester’s VP, Research Director Joseph Blankenship Security leaders are inundated with messages about artificial intelligence and its necessity in their organization’s security stack. While AI has come... 1 year ago | 63 mins Identification of unknown extractables and leachables using mass spectrometry... Petra Booij, Investigator at GlaxoSmithKline & Dr Kyle D’Silva, Pharma & BioPharma Marketing Leader, Thermo Fisher Scientific Full Title: Identification of unknown extractables and leachables using mass spectrometry: Identification with confidence? Extractable and Leachable ... 12 months ago | 57 mins Clinical and biochemical data-driven drug re-purposing for anti-infective drugs Andrey Khudoshin Drug repurposing has been shown to be advantageous for treating rare and common diseases. A data-driven drug repurposing approach may not only acceler... 1 year ago | 79 mins Looking towards 2021: Regulation, Rules, & Responsibility Nick Pratt, Roelfien Kuijpers, Eoin Motherway, Ken Owens Funds Europe’s Technology and Operations Editor Nicholas Pratt and a panel of experts discuss their views on the most urgent regulatory rules and resp... 8 months ago | 51 mins Honing Your Kraft: Enzymatic Treatment of UBK Fiber Using Novel Methods Mark Reed Packaging production is a complex process aiming at producing paper sheets from fibers with maximum strength at the lowest cost. After pulping, fibers... 1 year ago | 38 mins Identification of Approaches to Simulated Leachable Studies: What are They? W... Jason Creasey, Managing Director at Maven E&L and Karen Pieters, Ir. Team Leader E&L at Nelson Labs Europe Full Title: Identification of Approaches to Simulated Leachable Studies: What are They? When to do Them? Presented by Jason Creasey, Managing Directo... 1 year ago | 81 mins Threat Hunting - Hype or Substance Roselle Safran, UJ Desai and David Morris This session will cover the practice of Threat Hunting, when to use it, where to use it, and the technical skills needed to effectively deliver value ... 3 years ago | 65 mins A Comprehensive Approach to Assess the Impact of Microbial Impurities on Pat... Dr Friedrich von Wintzingerode, QC Lead iNeST Project at Roche and Shabnam Solati, CEO & Co-Founder at CTL-MAT FULL TITLE: A Comprehensive Approach to Assess the Impact of Microbial Impurities on Patient Safety and Product Quality of Biologics Presented by Dr ... 11 months ago | 80 mins Future Clarity: seeking certainty in the alternatives landscape Elliot Refson, Director of Funds,Jersey Finance; Romil Patel, Associate Director, Editor – Funds Global & ESG The indications are that, in the long-term, investors will continue to look to the alternative asset classes to achieve better returns, capture new op... 1 year ago | 44 mins Identification of unknown extractables and leachables using mass spectrometry... Petra Booij, Investigator at GlaxoSmithKline & Dr Kyle D’Silva, Pharma & BioPharma Marketing Leader, Thermo Fisher Scientific Full Title: Identification of unknown extractables and leachables using mass spectrometry: Identification with confidence? Extractable and Leachable ... 2 years ago | 58 mins ESG Risk & Reporting for Alternative Investments & EU Institutional Investors Jegor Tokarevich, CEO, SOF (Substance Over Form Ltd.) Content - Various ESG regulations and guidelines are currently under development on different EU and national levels - On the EU level “the big 4” is... 1 year ago | 50 mins Identification of Approaches to Simulated Leachable Studies Jason Creasey, Managing Director at Maven E&L and Karen Pieters, Ir. Team Leader E&L at Nelson Labs Europe Full Title: Identification of Approaches to Simulated Leachable Studies: What are They? When to do Them? Presented by Jason Creasey, Managing Directo... 12 months ago | 80 mins Next Generation Bioprocess Facility Design - A Case Study From Samsung Biologics Ken Green, Ph.D, Science and Technology at Samsung Biologics. John Bonham-Carter. Product Line Leader, Repligen A case study be presented describing initiatives and bioprocessing approaches to maximize capacity utilization within a new large scale (12x 15kL) dru... 9 months ago | 97 mins Elevate your image and impact from Zoom to the boardroom Tavia Sharp and Tania Sterl Presenting yourself on video calls can be more amplified and confronting than live meetings. How will you ensure you continue to be perceived as an ex... 1 year ago | 59 mins The Ubiquitous Nature of PFAS Demands Global Attention Seth Cutler, Frost & Sullivan, Nathan W. Hagelin, Vice President, Wood, and Francis Boodoo, Director, Purolite Corporation While the world is still determining the true extent and impact of PFAS (Per- and polyfluoroalkyl substances) on humans and the environment, responsib... 8 months ago | 62 mins Medical Cannabis: Riding Global Tailwinds Nawan Butt, Portfolio Manager at Purpose Investments and Andre Voinea, HANetf 2020 has marked a significant year for the cannabis market. With the pandemic leading to increased use of recreational and medicinal cannabis, Germany... 6 months ago | 54 mins Roundtable: Contributors to ASHP Controlled Substance Guidelines Share Insights Kimberly New, Toni Fera, JoAnne Myhre, Kim Dove, Bill Churchill We will be hosting a roundtable discussion with multiple thought leaders who have contributed to the ASHP Guidelines on Preventing Diversion of Contro... 4 years ago | 61 mins The TCE Revolution and Its Permanent Impact on Environmental Due Diligence David Gillay, Barnes & Thornburg; Dr. Michael Dourson, Ph.D., Alliance for Risk Assessment Following decades of studies, scrutiny and debate, the U.S. EPA updated its TCE’s toxicity profile in the IRIS database, dramatically lowering the tox... 6 years ago | 77 mins Webinar: The ‘content pinch point’ Billy Hamilton-Stent, Client strategy director, Octopus Group, marketing strategy In its annual Tech Heads study, Octopus Group spoke to over 400 UK directors to explore trends in content consumption and buyer behaviours for B2B bus... 5 years ago | 49 mins Don't Be the Next Headline - Regulatory Guidelines to Keep Compliant Kimberly New, JD, BSN, RN Do you know how to effectively manage medication processes to meet regulations related to drug diversion? We wrap up the 2015 webinar series by taking... 6 years ago | 60 mins Load more
